{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-000241","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.208759+00:00","generated_at":"2026-06-19T01:54:59.193527+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunic reports FY2022 net loss of $120.4M; cash $116.4M; goodwill impairment $33M","bullets":["Net loss $120.4M ($3.78/share) vs $92.9M ($3.93/share) in 2021; R&D expenses $71.3M.","Recorded non-cash goodwill impairment of $33M in Q4 2022 due to stock price decline after izumerogant psoriasis data.","Cash, equivalents and investments $116.4M as of Dec 31, 2022; expected to fund operations into Q4 2024.","Clinical milestones: IMU-856 celiac data mid-2023; CALLIPER progressive MS interim H2 2023; ENSURE relapsing MS interim late 2024.","Closed $60M private placement in Oct 2022 with new and existing institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-000241","json":"https://secwatch.observer/filing/0001193805-23-000241.json","markdown":"https://secwatch.observer/filing/0001193805-23-000241.md","text":"https://secwatch.observer/filing/0001193805-23-000241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/0001193805-23-000241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/e618296_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:54:59.193527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3443ab48abdc483daecfa59ccf88599359d3dfde","claim":"IMMUNIC, INC. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter and year ended December 31, 2022 and providing a corporate update (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/0001193805-23-000241-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}